The quest for an efficacious antiviral for respiratory syncytial virus

Antiviral Chemistry and Chemotherapy

Volumn 13, Issue 6, 2002, Pages 325-344

  Torrence, Paul F ^a   Powell, Linda D ^a  

^a NORTHERN ARIZONA UNIVERSITY   (United States)

Author keywords

2 5A; 2 5A antisense; Error threshold; Interferon; Lethal mutageneis; Membrane fusion; Morpholino nucleic acids; Nucleosides; Peptide nucleic acids; Ribavirin; RNase L

Indexed keywords

1 (2' DEOXYRIBOFURANOSYL) 3 NITROPYRROLE; 1,4 DIHYDRO 2,3 BENZODITHIIN; 2',5' OLIGOADENYLIC ACID; 4,4' BIS[4,6 BIS[3 (BISCARBAMOYLMETHYLSULFAMOYL)PHENYLAMINO] 1,3,5 TRIAZIN 2 YLAMINO]BIPHENYL 2,2' DISULFONIC ACID; ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; CL 387626; GAMMA INTERFERON; INTERFERON REGULATORY FACTOR 7; MEVINOLIN; MIZORIBINE; NUCLEIC ACID; PALIVIZUMAB; PEPTIDE NUCLEIC ACID; RD3 0028; RFI 641; RIBAMIDINE; RIBAVIRIN; RIBAVIRIN DERIVATIVE; RIBONUCLEASE; RIBONUCLEASE L; SELENAZOFURIN; SELENAZOLE; TIAZOFURIN; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN; VP 14637;

ANTIVIRAL ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; LETHAL MUTANT; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; STRUCTURE ANALYSIS; VIRUS GENOME; VIRUS INFECTION;

EID: 0037735313     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020201300601     Document Type: Review

References (225)

1. Aberle JH, Aberle SW, Dworzak MN, Mandl CYV, Rebhandl W, Vollnhofer G, Kundi M & Popow-Kraupp T (1999) Reduced interferon-gamma expression in peripheral blood mononuclear cells of infants with severe respiratory syncytial virus disease. American Journal of Respiratory Critical Care Medicine 160:1263-1268.
2. Adah SA, Bayly SF, Cramer H, Silverman RH & Torrence PF (2001) Chemistry and biochemistry of 2′,5′-oligoadenylate-based antisense strategy. Current Medicinal Chemistry 8:1189-1212.
3. Agarwal N & Gewirtz AM (1999) Oligonucleotide therapeutics for hematologic disorders. Biochimica et Biophysica Acta 1489:85-96.
4. Agatsuma T, Abe K, Furukawa H, Koga R, Koizumi M, Hotoda H & Kaneko M (1997) Protection of hu-PBL-SCID/beige mice from HIV-1 infection by a 6 mer modified oligonucleotide, R-95288. Antiviral Research 34:121-130.
5. Agatsuma T, Yamamoto I, Furukawa H & Nishigaki T (1996) Guanine-rich oligonucleotide modified at the 5′ terminal by dimethoxytrityl residue inhibits HIV-1 replication by specific interaction with the envelope glycoprotein. Antiviral Research 31:137-148.
6. Arora V, Cate ML, Ghosh C & Iversen PL (2002) Phosphorodiamidate morpholino antisense oligomers inhibit expression of human cytochrome P450 3A4 and alter selected drug metabolism. Drug Metabolism and Disposition 30:757-762.
7. Arora V, Knapp DC, Smith BL, Statdfield ML, Stein DA, Reddy MT, Weller DD & Iversen PL (2000) c-Myc antisense limits rat liver regeneration and indicates role for c-Myc in regulating cytochrome P-450 3A activity. Journal of Pharmacology and Experimental Therapeutics 292:921-928.
8. Arzumanov A WA, Rajwanshi VK, Kumar R, Wengel J, Gait MJ (2001) Inhibition of HIV-1 Tat-dependent trans activation by steric block chimeric 2′-O-methyl/LNA oligoribonucleotides. Biochemistry 40:14645-14654.
9. Barends M, Boelen A, de Rond L, Kwakkel J, Bestebroer T, Dormans J, Neijens H & Kimman T (2002) Influence of respiratory syncytial virus infection on cytokine and inflammatory responses in allergic mice. Clinical and Experimental Allergy 32:463-471.
10. Barnard DL, Sidwell RW, Xiao W, Player MR, Adah SA & Torrence PF (1999) 2-5A-DNA conjugate inhibition of respiratory syncytial virus replication: effects of oligonucleotide structure modifications and RNA target site selection. Antiviral Research 41:119-134.
11. Bates PJ, Kahlon JB, Thomas SD, Trent JO & Miller DM (1999) Antiproliferative activity of G-rich oligonucleotides correlates with protein binding. Journal of Biological Chemistry 274:26369-26377.
12. Behera AK, Kumar M, Lockey RF & Mohapatra SS (2002) 2′5′ Oligoadenylate synthetase plays a critical role in interferon-gamma inhibition of respiratory syncytial virus infection of human epithelial cells. Journal of Biological Chemistry 277:25601-25608.
13. Benimetskaya L, Tonkinson JL, Koziolkiewicz M, Karwowski B, Guga P, Zeltser R, Stec W & Stein CA (1995) Binding of phosphorothioate oligodeoxynucleotides to basic fibroblast growth factor, recombinant soluble CD4, laminin and fibronectin is P-chirality independent. Nucleic Acids Research 23:4239-4245.
14. Bergstrom DE, Zhang P & Johnson WT (1997) Comparison of the base pairing properties of a series of nitroazole nucleobase analogs in the oligodeoxyribonucleotide sequence 5′-d(CGCXAAT-TYGCG)-3′. Nucleic Acids Research 25:1935-1942.
15. Billings JL, Hertz MI, Savik K & Wendt CH (2002) Respiratory viruses and chronic rejection in lung transplant recipients. Journal of Heart and Lung Transplantation 21:559-566.
16. Billings JL, Hertz MI & Wendt CH (2001) Community respiratory virus infections following lung transplantation. Transplant Infectious Disease 3:138-148.
17. Bishop JS, Guy Caffey JK, Ojwang JO, Smith SR, Hogan ME, Cossum PA, Rando RF & Chaudhary N (1996) Intramolecular G-quartet motifs confer nuclease resistance to a potent anti-HIV oligonucleotide. Journal of Biological Chemistry 271:5698-56703.
18. Black RJ, Friedman RM, Imai J & Torrence PF (1985) Antagonism of 2-5 A-mediated inhibition of protein synthesis in intact cells by 2′,5′-(pA)3. FEBS Letters 191:154-158.
19. Boeckh M, Berrey MM, Bowden RA, Crawford SW, Balsley J & Corey L (2001) Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. Journal of Infectious Diseases 184:350-354.
20. Borowski P, Lang M, Niebuhr A, Haag A, Schmitz H, zur Wiesch JS, Choe J, Siwecka MA & Kulikowski T (2001) Inhibition of the helicase activity of HCV NTPase/helicase by 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide-5′-triphosphate (ribavirin-TP). Acta Biochimica Polonica 48:739-744.
21. Bossert B & Conzelmann KK (2002) Respiratory syncytial virus (RSV) nonstructural (NS) proteins as host range determinants: a chimeric bovine RSV with NS genes from human RSV is attenuated in interferon-competent bovine cells. Journal of Virology 76:4287-4293.
22. Braasch DA CD (2001) Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA. Chemistry and Biology 8:1-7.
23. Burgert HG RZ, Obermeier S, Hilgendorf A, Windheim M, Elsing A. (2002) Subversion of host defense mechanisms by adenoviruses. Current Topics in Microbiology and Immunology 269:273-318.
24. Cameron CE & Castro C (2001) The mechanism of action of ribavirin: lethal mutagenesis of RNA virus genomes mediated by the viral RNA-dependent RNA polymerase. Current Opinion in Infectious Diseases 14:757-764.
25. Chan DC & Kim PS (1998) HIV entry and its inhibition. Cell 93:681-684.
26. Chipps BE, Sullivan WF & Portnoy JM (1993) Alpha-2A-interferon for treatment of bronchiolitis caused by respiratory syncytial virus. Pediatric Infections Disease Journal 12:653-658.
27. Cirino NM, Li G, Xiao W, Torrence PF & Silverman RH (1997) Targeting RNA decay with 2′,5′ oligoadenylate-antisense in respiratory syncytial virus-infected cells. Proceedings of the National Academy of Sciences USA 94:1937-1942.
28. Clumeck N & Hermans P (1988) Antiviral drugs other than ziclovadine and immunomodulating therapies in human immunodeficiency virus infection. An overview. American Journal of Medicine 85:165-172.
29. Collins C & Pollard A (2002) Respiratory syncytial virus infections in children and adults. Journal of Infection 45:10.
30. Collins PL & Murphy BR (2002) Respiratory syncytial virus: reverse genetics and vaccine strategies. Virology 296:204-211.
31. Cook PD, Allen LB, Streeter DG, Huffman JH, Sidwell RW & Robins RK (1978) Synthesis and antiviral and enzymatic studies of certain 3-deazaguanines and their imidazolecarboxamide precursors. Journal of Medicinal Chemistry 21:1212-1218.
32. Cramer H, Player MR & Torrence PF (1999) Discrimination between ribonuclease H- and ribonuclease L-mediated RNA degradation by 2′-O-methylated 2-5A-antisense oligonucleotides. Bioorganic Medicinal Chemistry Letters 9:1049-1054.
33. Crotty S, Cameron C & Andino R (2002) Ribavirin's antiviral mechanism of action: lethal mutagenesis? Journal of Molecular Medicine 80:86-95.
34. Crowe Jr JE, Bui PT, Firestone CY, Connnors M, Elkins WR, Chanock RM & Murphy BR (1996) Live subgroup B respiratory syncytial virus vaccines that are attenuated, genetically stable, and immunogenic in rodents and nonhuman primates. Journal of Infectious Diseases 173:829-839.
35. De Clercq E, Billiau A, Edy VG, Kirk KL & Cohen LA (1978) Antimetabolic activities of 2-fluoro-L-histidine. Biochemistry and Biophysics Research Communication 82:840-846.
36. Dong B & Silverman RH (1995) 2-5A-dependent RNase molecules dimerize during activation by 2-5A. Journal of Biological Chemistry 270:4133-4137.
37. Dong B & Silverman RH (1997) A bipartite model of 2-5A-dependent RNase L. Journal of Biological Chemistry 272:22236-22242.
38. Dong B, Xu L, Zhou A, Hassel BA, Lee X, Torrence PF & Silverman RH (1994) Intrinsic molecular activities of the interferon-induced 2-5A-dependent RNase. Journal of Biological Chemistry 269:14153-14158.
39. Edell D, Khoshoo V, Ross G & Salter K (2002) Early Ribavarin Treatment of Bronchiolitis(*): Effect on Long-term Respiratory Morbidity. Chest 122:935-939.
40. Elayadi AN BD, Corey DR. (2002) Implications of high-affinity hybridization by locked nucleic acid oligomers for inhibition of human telomerase. Biochemistry 41:9973-9981.
41. Eriksson B, Helgstrand E, Johansson NG, Larsson A, Misiorny A, Noren JO, Philipson L, Stenberg K, Stening G, Stridh S & Oberg B (1977) Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrobial Agents and Chemotherapy 11:946-951.
42. Falsey AR & Walsh EE (2000) Respiratory syncytial virus infection in adults. Clinical Microbiology Reviews 13:371-384.
43. Fang SH, Lai MY, Hwang LH, Yang PM, Chen PJ, Chiang BL & Chen DS (2001) Ribavirin enhances interferon-gamma levels in patients with chronic hepatitis C treated with interferon-alpha. Journal of Biomedical Sciences 8:484-491.
44. Feldman SA, Audet S & Beeler JA (2000) The fusion glycoprotein of human respiratory syncytial virus facilitates virus attachment and infectivity via an interaction with cellular heparan sulfate. Journal of Virology 74:6442-6447.
45. Fernandez H, Banks G & Smith R (1986) Ribavirin: a clinical overview. European Jourrnal of Epidemiology 2:1-14.
46. Field K, Slavin MA & Seymour JF (2002) Severe respiratory syncytial virus pneumonia complicating fludarabine and cyclophosphamide treatment of chronic lymphocytic leukemia. European Journal of Haematology 69:54-57.
47. Garzon LS & Wiles L (2002) Management of respiratory syncytial virus with lower respiratory tract infection in infants and children. AACN Clinical Issues 13:421-430.
48. Gewirtz AM (1999a) Myb targeted therapeutics for the treatment of human malignancies. Oncogene 18:3056-3062.
49. Gewirtz AM (1999b) The prospects for antisense therapy. Hospital Practices (Off Edn.) 34:97-107; quiz 141.
50. Giles RV, Spiller DG, Clark RE & Tidd DM (1999) Antisense morpholino oligonucleotide analog induces missplicing of C-myc mRNA. Antisense Nucleic Acid Drug Development 9:213-220.
51. Goebel RJ, Adams AD, McKernan PA, Murray BK, Robins RK, Revankar GR & Canonico PG (1982) Synthesis and antiviral activity of certain carbamoylpyrrolopyrimidine and pyrazolopyrimidine nucleosides. Journal of Medicinal Chemistry 25:1334-1338.
52. Gotoh B KT, Takeuchi K, Yokoo J. (2001) Paramyxovirus accessory proteins as interferon antagonists. Microbiology and Immunology 45:787-800.
53. Gower T & Graham BS (2001) Antiviral activity of lovastatin against respiratory syncytial virus in vivo and in vitro. Antimicrobial Agents and Chemotherapy 45:1231-1237.
54. Graci JD & Cameron CE (2002) Quasispecies, error catastrophe, and the antiviral activity of ribavirin. Virology 298:175-180.
55. Grandvaux N tB, Servant MJ, Hiscott J. (2002) The interferon antiviral response: from viral invasion to evasion. Current Opinion in Infectious Diseases 15:259-267.
56. Greenough A (2002) Respiratory syncytial virus infection: clinical features, management, and prophylaxis. Current Opinion in Pulmonary Medicine 8:214-217.
57. Groothuis JR & Nishida H (2002) Prevention of respiratory syncytial virus infections in high-risk infants by monoclonal antibody (palivizumab). Pediatrics International 44:235-241.
58. Hall CB (2000) Nosocomial respiratory syncytial virus infections: the "Cold War" has not ended. Clinical Infections Diseases 31:590-596.
59. Han JQ BD (2002) Activation and evasion of the antiviral 2′-5′ oligoadenylate synthetase/ribonuclease L pathway by hepatitis C virus mRNA. RNA 8:512-525.
60. Harki DA, Graci JD, Korneeva VS, Ghosh SK, Hong Z, Cameron CE & Peterson BR (2002) Synthesis and antiviral evaluation of a mutagenic and non-hydrogen bonding ribonucleoside analogue: 1-beta-D-Ribofuranosyl-3-nitropyrrole. Biochemistry 41:9026-9033.
61. Haugh MCC, Cayley PJ, Serafinowska HT, Norman DG, Reese CB & Kerr IM (1983) Analogues and analogue inhibitors or ppp(A2′p)nA. Their stability and biological activity. European Journal of Biochemistry 132:77-84.
62. Heminway BR, Yu Y, Tanaka Y, Perrine KG, Gustafson E, Bernstein JM & Galinski MS (1994) Analysis of respiratory syncytial virus F, G, and SH proteins in cell fusion. Virology 200:801-805.
63. Higgins PG, Barrow GI, Tyrrell DA, Isaacs D & Gauci CL (1990) The efficacy of intranasal interferon alpha-2a in respiratory syncytial virus infection in volunteers. Antiviral Research 14:3-10.
64. Hotoda H, Koizumi M, Koga R, Kaneko M, Momota K, Ohmine T, Furukawa H, Agatsuma T, Nishigaki T, Sone J, Tsutsumi S, Kosaka T, Abe K, Kimura S & Shimada K (1998) Biologically active oligodeoxyribonucleotides. 5.5′-End-substituted d(TGGGAG) possesses anti-human immunodeficiency virus type 1 activity by forming a G-quadruplex structure. Journal of Medicinal Chemistry 41:3655-3663.
65. Hudziak RM, Summerton J, Weller DD & Iversen PL (2000) Antiproliferative effects of steric blocking phosphorodiamidate morpholino antisense agents directed against c-myc. Antisense Nucleic Acid Drug Development 10:163-176.
66. Huntley CC, Weiss WJ, Gazumyan A, Buklan A, Feld B, Hu W, Jones TR, Murphy T, Nikitenko AA, O'Hara B, Prince G, Quartuccio S, Raifield YE, Wyde P & O'Connell JF (2002) RFI-641, a potent respiratory syncytial virus inhibitor. Antimicrobial Agents and Chemotherapy 46:841-847.
67. Huynh-Dinh T, Igolen J, Bisagni E, Marquet JP & Civier A (1977) Synthesis of C-nucleosides. Part 14. 5(3)-Glycosyl-1,2,4-triazole-3(5)-carboxamides as analogues of ribavirin. Journal of the Chemical Society Perkin 1:761-764.
68. Imai J, Johnston MI & Torrence PF (1982a) Chemical modification potentiates the biological activities of 2-5A and its congeners. Journal of Biological Chemistry 257:12739-12745.
69. Imai J, Lesiak K, Johnston MI & Torrence PF (1982b) Oligonucleotide structural features involved in binding to and activation of the 2-5A-dependent endoribonuclease of L cells. Nucleic Acids Symposium Series:97-100.
70. Imai J, Lesiak K & Torrence PF (1984) Chemical synthesis and biological activities of partially inosine-substituted 2′5′-oligoadenylates: functional discrimination of three adenine amino groups on 2-5A for the binding to and activation of 2-5A-dependent endonuclease. Nucleic Acids Symposium Series:81-84.
71. Imai J, Lesiak K & Torrence PF (1985) Respective role of each of the purine N-6 amino groups of 5′-O-triphosphoryladenylyl(2′y- 5′)adenylyl(2 - 5′)adenosine in binding to and activation of RNase L. Journal of Biological Chemistry 260:1390-1393.
72. Imai J & Torrence PF (1981) An efficient chemical synthesis of adenylyl(2′ goes to 5′)adenylyl(2′ goes to 5′)adenosine [(2′-5′)-oligo(A)]. Methods in Enzymology 79:233-244.
73. Imai J & Torrence PF (1983) [Oligonucleotide structural features involved in binding to and activation of the 2-5 A-dependent endoribonuclease]. Tanpakushitsu Kakusan Koso 28:801-814.
74. Imai J & Torrence PF (1984) Synthesis and biological activity of 5′-capped derivatives of 5′-triphosphoadenylyl(2′- -5′)adenylyl(2′ - 5′)adenosine. Biochemistry 23:766-774.
75. Isaacs D (1989) Production of interferon in respiratory syncytial virus bronchiolitis. Archives of Disease in Childhood 64:92-95.
76. Ison MG & Hayden FG (2002) Viral infections in immunocompromised patients: what's new with respiratory viruses? Current Opinion in Infectious Diseases 15:355-367.
77. Jamoulle JC, Imai J, Lesiak K & Torrence PF (1984) Synthesis and biological activity of tubercidin analogues of ppp5′A2′p(5′A2′p)n5′A. Biochemistry 23:3063-3069.
78. Jamoulle JC, Lesiak K & Torrence PF (1987) Respective role of each of the purine N7 nitrogens of 5′-O- triphosphoadenylyl(2′-5′)adenylyl(2′ - 5′)adenosine in binding to and activation of the RNase L of mouse cells. Biochemistry 26:376-383.
79. Jing N (2000) Developing G-quartet oligonucleotides as novel anti-HIV agents: focus on anti-HIV drug design. Expert Opinion on Investigational Drugs 9:1777-1785.
80. Jing N, De Clercq E, Rando RF, Pallansch L, Lackman-Smith C, Lee S & Hogan ME (2000a) Stability-activity relationships of a family of G-tetrad forming oligonucleotides as potent HIV inhibitors. A basis for anti-HIV drug design. Journal of Biological Chemistry 275:3421-3430.
81. Jing N, Marchand C, Guan Y, Liu J, Pallansch L, Lackman-Smith C, De Clercq E & Pommier Y (2001) Structure-activity of inhibition of HIV-1 integrase and virus replication by G quartet oligonucleotides. DNA and Cell Biology 20:499-508.
82. Jing N, Marchand C, Liu J, Mitra R, Hogan ME & Pommier Y (2000b) Mechanism of inhibition of HIV-1 integrase by G-tetrad-forming oligonucleotides in vitro. Journal of Biological Chemistry 275:21460-21467.
83. Kahn JS (2000) Respiratory syncytial virus vaccine development. Current Opinion in Pediatrics 12:257-262.
84. Kariko K, Li SW, Sobol RW, Jr., Suhadolnik RJ, Charubala R & Pfleiderer W (1987a) Phosphorothioate analogues of 2′,5′-oligoad-enylate. Activation of 2′,5′-oligoadenylate-dependent endoribonuclease by 2′,5′-phosphorothioate cores and 5′-monophosphates. Biochemistry 26:7136-7142.
85. Kariko K, Sobol RW, Jr., Suhadolnik L, Li SW, Reichenbach NL, Suhadolnik RJ, Charubala R & Pfleiderer W (1987b) Phosphorothioate analogues of 2′,5′ oligoadenylate. Enzymatically synthesized 2′,5′-phosphorothioate dimer and trimer: unequivocal structural assignment and activation of 2′,5′-oligoadenylate-dependent endoribonuclease. Biochemistry 26:7127-7135.
86. Karron RA, Buonagurio DA, Georgiu AF, Whitehead SS, Adamus JE, Clements-Mann ML, Harris DO, Randolph VB, Udem SA, Murphy BR & Sidhu MS (1997) Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proceedings of the National Academy of Sciences USA 94:13961-13966.
87. Katze M, Yupeng, H, Gale, M (2002) Viruses and Interferon: A Fight for Supremacy. Nature Reviews Immunology 2:675-687.
88. Keniry MA (2000) Quadruplex structures in nucleic acids. Biopolymers 56:123-146.
89. Khaled Z, Benimetskaya L, Zeltser R, Khan T, Sharma HW, Narayanan R & Stein CA (1996) Multiple mechanisms may contribute to the cellular anti-adhesive effects of phosphorothioate oligodeoxynucleotides. Nucleic Acids Research 24:737-745.
90. Khushalani NI, Bakri FG, Wentling D, Brown K, Mohr A, Anderson B, Keesler C, Ball D, Bernstein ZP, Bernstein SH, Czuczman MS, Segal BH & McCarthy PL, Jr. (2001) Respiratory syncytial virus infection in the late bone marrow transplant period: report of three cases and review. Bone Marrow Transplant 27:1071-1073.
91. Kimpen JL (2001) Management of respiratory syncytial virus infection. Current Opinion in Infectious Diseases 14:323-328.
92. Kini GD, Robins RK & Avery TL (1989) Synthesis and antitumor activity of ribavirin imidates. A new facile synthesis of ribavirin amidine (1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamidine hydrochloride). Journal of Medicinal Chemistry 32:1447-1449.
93. Kitade Y, Nakata Y, Hirota K, Maki Y, Pabuccoglu A & Torrence PF (1989) 8-Methyladenosine-substituted analogs of 2-5A: synthesis and properties. Nucleic Acids Symposium Series 21:93-94.
94. Kitade Y, Nakata Y, Hirota K, Maki Y, Pabuccuoglu A & Torrence PF (1991) 8-Methyladenosine-substituted analogues of 2-5A: synthesis and their biological activities. Nucleic Acids Research 19:4103-4108.
95. Kondo S, Kondo Y, Li G, Silverman RH & Cowell JK (1998) Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA. Oncogene 16:3323-3330.
96. Kondo Y; Koga S; Komata T; Kondo S (2000) Treatment of prostate cancer in vitro and in vivo with 2-5A-anti-telomerase RNA component. Onrogene 19:2205-2211.
97. Krause D, Lesiak K, Imai J, Sawai H, Torrence PF & Silverman RH (1985) Structure-activity relationship of analogs of 2-5A determined using the core-cellulose assay for 2-5A-dependent RNase.." Progress in Clinical and Biological Research 202:133-139.
98. Krause D, Lesiak K, Imai J, Sawai H, Torrence PF & Silverman RH (1986) Activation of 2-5A-dependent RNase by analogs of 2-5A (5′-O-triphosphoryladenylyl(2′ - 5′)adenylyl(2′ - 5′)adenosine) using 2′,5′-tetraadenylate (core) cellulose. Journal of Biological Chemistry 261:6836-6839.
99. Krieg AM & Stein CA (1995) Phosphorothioate oligodeoxynucleotides: antisense or anti-protein? Antisense Research and Development 5:241.
100. Krieg AM, Tonkinson J, Matson S, Zhao Q, Saxon M, Zhang LM, Bhanja U, Yakubov L & Stein CA (1993) Modification of anti-sense phosphodiester oligodeoxynucleotides by a 5′ cholesteryl moiety increases cellular association and improves efficacy. Proceedings of the National Academy of Science USA 90:1048-1052.
101. Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G & Petteway Jr. SR (1996) Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proceedings of the National Academy of Sciences USA 93:2186-2191.
102. Lanford RE, Chavez D, Guerra B, Lau JY, Hong Z, Brasky KM & Beames B (2001) Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes. Journal of Virology 75:8074-8081.
103. Leaman DW, Longano FJ, Okicki JR, Soike KF, Torrence PF, Silverman RH & Cramer H (2002) Targeted therapy of respiratory syncytial virus in African green monkeys by intranasally administered 2-5A antisense. Virology 292:70-77.
104. Lebedeva I & Stein CA (2001) Antisense oligonucleotides: promise and reality. Annual Review of Pharmacology and Toxicology 41:403-419.
105. Lesiak K, Imai J, Floyd-Smith G & Torrence PF (1983) Biological activities of phosphodiester linkage isomers of 2-5A. Journal of Biological Chemistry 258:13082-13088.
106. Lesiak K, Khamnei S & Torrence PF (1993) 2′,5′-Oligoadenylate: antisense chimeras - synthesis and properties. Bioconjugate Chemistry 4:467-472.
107. Lesiak K & Torrence PF (1983) Synthesis and biological activity of a fluorescent analogue of 2-5A. FEBS Letters 151:291-296.
108. Lesiak K & Torrence PF (1985) Phosphorylation of 2-5A core 5′-diphosphate to 2-5A in mouse L cell extracts. Biochemical and Biophysical Research Communications 126:917-921.
109. Lesiak K & Torrence PF (1986) Synthesis and biological activities of oligo(8 bromoadenylates) as analogues of 5′-O-triphosphoadenylyl(2′ - 5′)adenylyI(2′ - 5′)adenosine. Journal of Medicinal Chemistry 29:1015-1022.
110. Lesiak K & Torrence PF (1987) Purine 8-bromination modulates the ribonuclease L binding and activation abilities of 2′,5′-oligoadenylates. Possible influence of glycosyl torsion angle. Journal of Biological Chemistry 262:1961-1965.
111. Li G, Xiao W & Torrence PF (1997) Synthesis and properties of second-generation 2-5A-antisense chimeras with enhanced resistance to exonucleases. Journal of Medicinal Chemistry 40:2959-2966.
112. Maag D, Castro C, Hong Z & Cameron CE (2001) Hepatitis C virus RNA dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. Journal of Biological Chemistry 276:46094-46098.
113. Maitra RK, Li G, Xiao W, Dong B, Torrence PF & Silverman RH (1995) Catalytic cleavage of an RNA target by 2-5A antisense and RNase L. Journal of Biological Chemistry 270:15071-15075.
114. Maran A, Maitra RK, Kumar A, Dong B, Xiao W, Li G, Williams BR, Torrence PF & Silverman RH (1994) Blockage of NF-kappa B signaling by selective ablation of an mRNA target by 2-5A anti-sense chimeras. Science 265:789-792.
115. Marquardt DL, Gruber HE & Walker LL (1987) Ribavirin inhibits mast cell mediator release. Journal of Pharmacological Experimental Therapeutics 240:145-149.
116. Martinello RA, Chen MD, Weibel C & Kahn JS (2002) Correlation between Respiratory Syncytial Virus Genotype and Severity of Illness. Journal of Infectious Diseases 186:839-842.
117. McKimm-Breschkin J (2000) VP-14637 ViroPharma. Current Opinion in Investigational Drugs 1:425-427.
118. Meanwell NA & Krystal M (2000) Respiratory syncytial virus: recent progress towards the discovery of effective prophylactic and therapeutic agents. Drug Discovery Today 5:241-252.
119. Merolla R, Rebert NA, Tsiviste PT, Hoffmann SP & Panuska JR (1995) Respiratory syncytial virus replication in human lung epithelial cells: inhibition by tumor necrosis factor alpha and interferon beta. American Journal of Respiratory Critical Care Medicine 152:1358-1366.
120. Message SD & Johnston SL (2002) Viruses in asthma. British Medical Bulletin 61:29-43.
121. Miyamoto NGJ, Jacobs BL & Samuel CE (1983) Mechanism of interferon action. Effect of double-stranded RNA and the 5′-O-monophosphate form of 2′,5′ oligoadenylate on the inhibition of reovirus mRNA translation in vitro. Journal of Biological Chemistry 258:15232-15237.
122. Mukai S, Kondo Y, Koga S, Komata T, Barna BP & Kondo S (2000) 2-5A antisense telomerase RNA therapy for intracranial malignant gliomas. Cancer Research 60:4461-4467.
123. Murphy BR & Collins PL (2002) Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics. Journal of Clinical Investigation 110:21-27.
124. Nakano K & Cinader B (1980) Effect of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin) on tolerance induction in SJL mice. Immunopharmacology 2:157-164.
125. Nakayama T, Sonoda S, Urano T, Sasaki K, Maehara N & Makino S (1993) Detection of alpha-interferon in nasopharyngeal secretions and sera in children infected with respiratory syncytial virus. Pediatric Infectious Disease Journal 12:925-929.
126. Narang AS & Vince R (1977) 1,2,4-Triazole amino nucleosides. 1-beta-D-3′-Amino-3′-deoxyribofuranosyl-1,2,4 triazole-3-carboxamide and related nucleosides. Journal of Medicinal Chemistry 20:1684-1687.
127. Nikitenko AA, Raifield YE & Wang TZ (2001) The discovery of RFI-641 as a potent and selective inhibitor of respiratory syncytial virus. Bioorganic & Medicinal Chemistry Letters 11:1041-1044.
128. Nyce J & Metzger, WZ (1997) DNA antisense therapy for asthma in an animal model. Nature 385:721-725.
129. Orum H WJ (2001) Locked nucleic acids: a promising molecular family for gene function analysis and antisense drug development. Current Opinion in Molecular Therapeutics 3:239-243.
130. Park HJ & Galper JB (1999) 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors up-regulate transforming growth factor beta signaling in cultured heart cells via inhibition of geranylgeranylation of RhoA GTPase. Proceedings of the Naitonal Academy of Sciences USA 96:11525-11530.
131. Pastey M, Gower T, Spearman P, Crowe P & Graham B (2000) RhoA-derived peptide inhibits syncytium formation induced by respiratory syncytial virus and parainfluenza virus type 3. Nature Medicine 6:35-40.
132. Pastey MK, Crowe JE Jr & Graham BS (1999) RhoA interacts with the fusion glycoprotein of respiratory syncytial virus and facilitates virus-induced syncytium formation. Journal of Virology 73:7262-7270.
133. Patterson JL & Fernandez-Larsson R (1990) Molecular mechanisms of action of ribavirin. Reviews of Infectious Diseases 12:1139-1146.
134. Peyman ARA, Helsburg M, Kretschmar G, Mag M, Ryte A Uhlmann E (1995) Enhanced cellular uptake of G-rich oligonucleotides. Nucleosides and Nucleotides 14:1070-1081.
135. Piedimonte G (2002) The association between respiratory syncytial virus infection and reactive airway disease. Respiratory Medicine 96(Suppl. B):S25-S29.
136. Pitkaranta A & Hovi T (1993) Induction of interferon in human leukocyte cultures by natural pathogenic respiratory viruses. Journal of Interferon Research, 13:423-426.
137. Player MR, Barnard DL & Totrence PF (1998) Potent inhibition of respiratory syncytial virus replication using a 2-5A-antisense chimera targeted to signals within the virus genomic RNA. Proceedings of the Naitonal Academy of Sciences USA 95:8874-8879.
138. Player MR & Torrence PF (1998) The 2-5A system: modulation of viral and cellular processes through acceleration of RNA degradation. Pharmacology and Therapeutics 78:55-113.
139. Player MR & Torrence PF (1999) Phosphorothioate oligodeoxyribonucleotides inhibit ribonuclease L thereby disabling a mechanism of interferon action. Bioorganic & Medicinal Chemistry Letters 9:891-894.
140. Prince G (2001) An update on respiratory syncytial virus antiviral agents. Expert Opinion on Investigational Drugs 10:297-308.
141. Qin G, Taylor M, Ning YY, Iversen P & Kobzik L (2000) in vivo evaluation of a morpholino antisense oligomer directed against tumor necrosis factor-alpha. Antisense Nucleic Acid Drug Development 10:11-16.
142. Rankin JT Jr, Eppes SB, Antczak JB & Joklik WK (1989) Studies on the mechanism of the antiviral activity of ribavirin against reovirus. Virology 168:147-158.
143. Razinkov V, Gazumyan A, Nikitenko AA, Ellestad G & Krishnamurthy G (2001) RFI-641 inhibits entry of respiratory syncytial virus via interactions with fusion protein. Chemistry & Biology 8:645-659.
144. Revankar GR & Robins RK (1975) Synthesis and biological activity of some nucleosides resembling guanosine: imidazo(1,2-alpha)pyrimidine nucleosides. Annals of the New York Academy of Sciences 255:166-176.
145. Robbins I, Mitta G, Vichier-Guerre S, Sobol R, Ubysz A, Rayner B & Lebleu B (1998) Selective mRNA degradation by antisense oligonudeotide-2,5A chimeras: involvement of RNase H and RNase L. Biochimie 80:711-720.
146. Roberts NJ Jr, Hiscott J & Signs DJ (1992) The limited role of the human interferon system response to respiratory syncytial virus challenge: analysis and comparison to influenza virus challenge. Microbial Pathogenesis 12:409-414.
147. Ruef C (2002) Respiratory syncytial virus infections - an underdiagnosed entity? Infection 30:185.
148. Sanghvi YS, Hanna NB, Larson SB, Fujitaki JM, Willis RC, Smith RA, Robins RK & Revankar GR (1988) Synthesis and evaluation of 5-amino-1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamidine and certain related nucleosides as inhibitors of purine nucleoside phosphorylase. Journal of Medicinal Chemistry 31:330-335.
149. Sawai H, Imai J, Lesiak K, Johnston MI & Torrence PF (1983) Cordycepin analogues of 2-5A and its derivatives. Chemical synthesis and biological activity. Journal of Biological Chemistry 258:1671-1677.
150. Sawai H, Lesiak K, Imai J & Torrence PF (1985) Replacement of the ribofuranose oxygen of 2-5A derivatives by methylene: synthesis of an aristeromycin analogue of 2-5A core 5′-monophosphate (5′O-phosphoryladenylyl)(2′ - 5′)adenyl(2′ - 5′)adenosine. Journal of Medicinal Chemistry 28:1376-1380.
151. Sharma OK, Goswami BB & Borek E (1982) Inhibition of mRNA methylation: an approach to specific inhibition of vital replication. Princess Takamatsu Symposium 12:109-116.
152. Shors ST BE, Paoletti E, Tartaglia J, Jacobs BL. (1998) Role of the vaccinia virus E3L and K3L gene products in rescue of VSV and EMCV from the effects of IFN-alpha. Journal of Interferon and Cytokine Research 18:721-729.
153. Sidwell RW, Robins RK & Hillyard IW (1979) Ribavirin: an antiviral agent. Pharmacology and Therapeutics 6:123-146.
154. Sigurs N (2002) Clinical perspectives on the association between respiratory syncytial virus and reactive airway disease. Respiratory Research 3(Suppl. 1):S8-S14.
155. Silverman RH (1994) Fascination with 2-5A dependent RNase: a unique enzyme that functions in interferon action. Journal of Interferon Research 14:101-104.
156. Silverman RH, Dong B, Maitra RK, Player MR & Torrence PF (2000) Selective RNA cleavage by isolated RNase L activated with 2-5A antisense chimeric oligonucleotides. Methods in Enzymology 313:522-533.
157. Silverman RH, Zhou A, Auerbach MB, Kish D, Gorbachev A & Fairchild RL (2002) Skin allograft rejection is suppressed in mice lacking the antiviral enzyme, 2′,5′-oligoadenylate-dependent RNase L. Viral Immunology 15:77-83.
158. Simoes EA & Groothuis JR (2002) Respiratory syncytial virus prophylaxis - the story so far. Respiratory Medicine 96(Suppl. B):S15-S24.
159. Sintchak MD & Nimmesgern E (2000) The structure of inosine 5′-monophosphate dehydrogenase and the design of novel inhibitors. Immunopharmacology 47:163-184.
160. Smejkal RM, Page TT, Boyd VL, Nyhan WL, Jacobsen SJ, Mangum JH & Robins RK (1984) Novel nucleoside inhibitors of guanosine metabolism as antitumor agents. Advances in Enzyme Regulation 22:59-68.
161. Souvignet C ZJ (2000) Combination treatment for chronic hepatitis C: what is the role of ribavirin? Fundamental and Clinical Pharmacology 14:321-325.
162. Srivastava PC, Ivanovics GA, Rousseau RJ & Robins RK (1975) Nucleosides of 4-substituted imidazoles. Journal of Organic Chemistry 40:2920-2924.
163. Srivastava PC, Pickering MV, Allen LB, Streeter DG, Campbell MT, Witkowski JT, Sidwell RW & Robins RK (1977) Synthesis and antiviral activity of certain thiazole C-nucleosides. Journal of Medicinal Chemistry 20:256-262.
164. Srivastava PC, Revankar GR & Robins RK (1984) Synthesis and biological activity of nucleosides and nucleotides related to the antitumor agent 2-beta-D-ribofuranosylthiazole-4-carboxamide. Journal of Medicinal Chemistry 27:266-269.
165. Stark GR, Kerr IM, Williams BR, Silverman RH & Schreiber RD (1998) How cells respond to interferons. Annual Review of Biochemistry 67:227-264.
166. Stein CA (1992) Anti-sense oligodeoxynucleotides - promises and pitfalls. Leukemia 6:967-974.
167. Stein CA (1996) Phosphorothioate antisense oligodeoxynucleotides: questions of specificity. Trends in Biotechnology 14:147-149.
168. Stein CA (1997) Controversies in the cellular pharmacology of oligodeoxynucleotides. Ciba Foundation Symposium 209:79-89; discussion 89-93.
169. Stein CA (2001) The experimental use of antisense oligonucleotides: a guide for the perplexed. Journal of Clinical Investigation 108:641-644.
170. Stein CA & Cheng YC (1993) Antisense oligonucleotides as therapeutic agents - is the bullet really magical? Science 261:1004-1012.
171. Stein CA & Krieg AM (1994) Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Research and Development 4:67-69.
172. Stein D, Foster E, Huang SB, Weller D & Summerton J (1997) A specificity comparison of four antisense types: morpholino, 2′-O methyl RNA, DNA, and phosphorothioate DNA. Antisense Nucleic Acid Drug Development 7:151-157.
173. Storer R, Ashton CJ, Baxter AD, Hann MM, Marr CL, Mason AM, Mo CL, Myers PL, Noble SA, Penn CR, Weir NG, Woods JM & Coe PL (1999) The synthesis and antiviral activity of 4-fluoro-1-beta-D-ribofuranosyl-1H-pyrazole-3-carboxamide. Nucleosides and Nucleotides 18:203-216.
174. Sudo K, Konno K, Watanabe W, Shigeta S & Yokota T (2001) Mechanism of selective inhibition of respiratory syncytial virus by a benzodithiin compound (RD3-0028). Microbiological Immunology 45:531-537.
175. Sudo K, Watanabe W, Konno K, Sato R, Kajiyashiki T, Shigeta S & Yokota T (1999) Efficacy of RD3-0028 aerosol treatment against respiratory syncytial virus infection in immunosuppressed mice. Antimicrobial Agents and Chemotherapy 43:752-757.
176. Sudo K, Yoshida K, Konno K, Nommiya S, Hibino M, Shigeta S & Yokota T (2002) Pharmacokinetics of a benzodithiin (RD3-0028) following aerosol treatment in rat. Xenobiotica 32:19-27.
177. Summerton J (1999) Morpholino antisense oligomers: the case for an RNase H-independent structural type. Biochimica et Biophysica Acta 1489:141-158.
178. Summerton J, Stein D, Huang SB, Matthews P, Weller D & Partridge M (1997) Morpholino and phosphorothioate antisense oligomers compared in cell-free and in-cell systems. Antisense Nucleic Acid Drug Development 7:63-70.
179. Summerton J & Weller D (1997) Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Development 7:187-95.
180. Sung RY, Yin J, Oppenheimer SJ, Tam JS & Lau J (1993) Treatment of respiratory syncytial virus infection with recombinant interferon alfa-2a. Archives of Disease in Childhood 69:440-442.
181. Swedish Consensus Group (2001) Management of infections caused by respiratory syncytial virus. Scandinavian Journal of Infectious Diseases 33:323-328.
182. Tam RC LJ, Hong Z. (2001) Mechanisms of action of ribavirin in antiviral therapies. Antiviral Chemistry & Chemotherapy 12:261-272.
183. Taylor CE, Webb MS, Milner AD, Milner PD, Morgan LA, Scott R, Stokes GM, Swarbrick AS & Toms GL (1989) Interferon alfa, infectious virus, and virus antigen secretion in respiratory syncytial virus infections of graded severity. Archives of Disease in Childhood 64:1656-1660.
184. Taylor MF, Paulauskis JD, Weller DD & Kobzik L (1996) In vitro efficacy of morpholino-modified antisense oligomers directed against tumor necrosis factor alpha mRNA. Journal of Biological Chemistry 271:17445-17452.
185. Taylor MF, Paulauskis JD, Weller DD & Kobzik L (1997) Comparison of efficacy of antisense oligomers directed toward TNF-alpha in helper T and macrophage cell lines. Cytokine 9:672-681.
186. Taylor MF, Weller DD & Kobzik L (1998) Effect of TNF-alpha antisense oligomers on cytokine production by primary murine alveolar macrophages. Antisense Nucleic Acid Drug Development 8:199-205.
187. Toltzis P & Huang AS (1986) Effect of ribavirin on macromolecular synthesis in vesicular stomatitis virus-infected cells. Antimicrobial Agents and Chemotherapy 29:1010-1016.
188. Tonkinson JL & Stein CA (1996) Antisense oligodeoxynucleotides as clinical therapeutic agents. Cancer Investigation 14:54-65.
189. Torrence PF (1999) 2-5A-antisense chimeras: inhibitors of respiratory syncytial virus infection. Current Opinion in Molecular Therapeutics 1:307-315.
190. Torrence PF, Brozda D, Alster D, Charubala R & Pfleiderer W (1988) Only one 3′-hydroxyl group of ppp5′ A2′p5′A2′p5′A (2-5A) is required for activation of the 2-5A-dependent endonuclease. Journal of Biological Chemistry 263:1131-1139.
191. Torrence PF, Brozda D, Alster DK, Pabuccuoglu A & Lesiak K (1992) A new and potent 2-5A analogue which does not require a 5′-polyphosphate to activate mouse L-cell RNase L. Antiviral Research 18:275-289.
192. Torrence PF, Imai J, Jamoulle JC, Wong A & Lesiak K (1985) Sequence-specific 2′5′-oligonucleotides in the molecular dissection of the biological activity of2-5A. Progress in Clinical and Biological Research 202:75-80.
193. Torrence PF, Imai J & Johnston MI (1981) 5′O-Monophosphoryladenylyl(2′ goes to 5′)adenylyl(2′ 5′)adenyl (2′ goes to 5′)adenosine is an antagonist of the action of 5′-O-triphosphoryladenylyl-(2′ goes to 5′)adenylyl(2′ goes to 5′)adenosine and double-stranded RNA. Proceedings of the National Academy of Sciences USA 78:5993-5997.
194. Torrence PF, Imai J, Lesiak K, Jamoulle JC & Sawai H (1984) Oligonucleotide structural parameters that influence binding of 5′-O-triphosphoadenylyl-(2′-5′)-adenylyl-(2′- 5′)-adenosine to the 5′-O-triphosphoadenylyl-(2′ - 5′)-adenylyl-(2′ 5′)-adenosine dependent endoribonuclease: chain length, phosphorylation state, and heterocyclic base. Journal of Medicinal Chemistry 27:726-233.
195. Torrence PF, Maitra RK, Lesiak K, Khamnei S, Zhou A & Silverman RH (1993) Targeting RNA for degradation with a (2′-5′)oligoadenylate-antisense chimera. Proceedings of the National Academy of Sciences USA 90:1300-1304.
196. Torrence PF & Wang Z (2001) Accelerating RNA decay through intervention of RNase L: alternative synthesis of composite 2′,5′-oligoadenylate-antisense. Methods in Enzymology 342:20-28.
197. Torrence PF, Xiao W, Li G, Cramer H, Player MR & Silverman RH (1997) Recruiting the 2-5A system for antisense therapeutics. Antisense Nucleic Acid Drug Development 7:203-206.
198. Tsilevich TL, Kochetkova SV, Shchaveleva IL, Smirnov IP & Gottikh BP (1987) [Synthesis and properties of acyclic analogs of ribavirin]. Bioorganicheskaia Khimiia 13:1240-1244.
199. van Schaik SM, Obot N, Enhorning G, Hintz K, Gross K, Hancock GE, Stack AM & Welliver RC (2000a) Role of interferon gamma in the pathogenesis of primary respiratory syncytial virus infection in BALB/c mice. Journal of Medical Virology 62:257-266.
200. van Schaik SM, Welliver RC & Kimpen JL (2000b) Novel pathways in the pathogenesis of respiratory syncytial virus disease. Pediatric Pulmonology 30:131-138.
201. Van Woensel JB KJ, Brand PL. (2001) Respiratory tract infections caused by respiratory syncytial virus in children. Diagnosis and treatment. Minerva Pediatrica 53:99-106.
202. Verheijen JC, Bayly SF, Player MR, Torrence PF, van der Marel GA & van Boom JH (1999a) 2-5A-PNA complexes: a novel class of antisense compounds. Nucleosides and Nucleotides 18:1485-1486.
203. Verheijen JC, Chen L, Bayly SF, Torrence PF, van der Marel GA & van Boom JH (2000a) Synthesis and RNAse L binding and activation of a 2-5A-(5′)-DNA-(3′)-PNA chimera, a novel potential antisense molecule. Nucleosides Nucleotides and Nucleic Acids 19:1821-1830.
204. Verheijen JC, van der Marel GA, van Boom JH, Bayly SF, Player MR & Torrence PF (1999b) 2,5-oligoadenylate-peptide nucleic acids (2-5A-PNAs) activate RNase L. Bioorganic & Medicinal Chemistry Letters 7:449-455.
205. Verheijen JC, van Roon AM, Meeuwenoord NJ, Stuivenberg HR, Bayly SF, Chen L, van der Marel GA, Torrence PF & van Boom JH (2000b) Incorporation ofa 4-hydroxy-N-acetylprolinol nucleotide analogue improves the 3′-exonuclease stability of 2′-5′-oligoadenylate-antisense conjugates. Bioorganic & Medicinal Chemistry Letters 10:801-804.
206. Vijayaiakshmi KS & Yathindra N (1980) Conformational analysis of nucleoside and nucleotide antibiotics prossessing five-membered base rings. A comparison of the glycosyl barrier for purine, pyrimidine and imidazole rings. Biochimica et Biopbysica Acta 607:171-180.
207. Vujovic O & Mills J (2001a) Preventive and therapeutic strategies for respiratory syncytial virus infection. Current Opinion in Pharmacology 1:497-503.
208. Wang W, Chen HJ, Sun J, Benimetskaya L, Schwartz A, Cannon P, Stein CA & Rabbani LE (1998) A comparison of guanosine-quartet inhibitory effects versus cytidine homopolymer inhibitory effects on rat neointimal formation. Antisense Nucleic Acid Drug Development 8:227-236.
209. Wang Z, Chen L, Bayly SF & Torrence PF (2000) Convergent synthesis of ribonuclease L-active 2′,5′-oligoadenylate peptide nucleic acids. Bioorganic & Medicinal Chemistry Letters 10:1357-1360.
210. Watanabe W, Sudo K, Sato R, Kajiyashiki T, Konno K, Shigeta S & Yokota T (1998) Novel anti-respiratory syncytial (RS) viral compounds: benzodithiin derivatives. Biochemical and Biophysical Research Communications 249:922-926.
211. Whimbey E & Ghosh S (2000) Respiratory syncytial virus infections in immunocompromised adults. Current Clinical Topics in Infectious Diseases 20:232-55.
212. Wood SG, Upadhya KG, Dalley NK, McKernan PA, Canonico PG, Robins RK & Revankar GR (1985) Synthesis and biological activity of 5 thiobredinin and certain related 5-substituted imidazole-4-carboxamide ribonucleosides. Journal of Medicinal Chemistry 28:1198-1203
213. Wray SK, Gilbert BE & Knight V (1985) Effect of ribavirin triphosphate on primer generation and elongation during influenza virus transcription in vitro. Antiviral Research 5:39-48.
214. Wyde PR, Moore-Poveda DK, O'Hara B, Ding W-D, Mitsner B & Gilbert BE (1998) CL387626 exhibits marked and unusual antiviral activity against respiratory syncytial virus in tissue culture and in cotton rats. Antiviral Research 38:31-42.
215. Xiang Y, Condit RC, Vijaysri S, Jacobs B, Williams BR & Silverman RH (2002) Blockade of interferon induction and action by the E3L double-stranded RNA binding proteins of vaccinia virus. Journal of Virology 76:5251-5259.
216. Xiao W LG, Lesiak K, Dong B, Silverman RH, Torrence PF: (1994) Synthesis of a 5′-thiophosphate analogue of 2-5A, a phosphatase resistant activator of the 2-5A-dependent ribonuclease. Bioorganic Medicinal Chemistry Letters 4:2609-2614.
217. Xiao W, Li G, Maitra RK, Maran A, Silverman RH & Torrence PF (1997) Correlation of selective modifications to a 2′,5′-oligoadenylate-3′,5′-deoxyribonucleotide antisense chimera with affinity for the target nucleic acid and with ability to activate RNase L. Journal of Medicinal Chemistry 40:1195-1200.
218. Xue Q, Liu S, Yuan Y, Guo L, Guan J & Wang B (2002) [A study on viral infections in patients with chronic obstructive pulmonary disease]. Zhonghua Jie He He Hu Xi Za Zhi 25:341-343.
219. Young DF, Didcock L, Goodbourn S & Randall RE (2000) Paramyxoviridae use distinct virus-specific mechanisms to circumvent the interferon response. Virology 269:383-390.
220. Zhao X, Singh M, Malashkevich VN & Kim PS (2000) Structural characterization of the human respiratory syncytial virus fusion protein core. Proceedings of the National Academy of Sciences USA 97:14172-14177.
221. Zheng X, Silverman RH, Zhou A, Goto T, Kwon BS, Kaufman HE & Hill JM (2001) Increased severity of HSV-1 keratitis and mortality in mice lacking the 2-5A dependent RNase L gene. Investigative Ophthalmology and Visual Science 42:120-126.
222. Zhou A, Paranjape J, Brown TL, Nie H, Naik S, Dong B, Chang A, Trapp B, Fairchild R, Colmenares C & Silverman RH (1997) Interferon action and apoptosis are defective in mice devoid of 2′,5′-oligoadenylate-dependent RNase L. The EMBO Journal 16:6355-6363.
223. Zhou A, Paranjape JM, Der SD, Williams BR & Silverman RH (1999) Interferon action in triply deficient mice reveals the existence of alternative antiviral pathways. Virology 258:435-440.
224. Zhou A, Paranjape JM, Hassel BA, Nie H, Shah S, Galinski B & Silverman RH (1998) Impact of RNase L overexpression on viral and cellular growth and death. Journal of Interferon and Cytokine Research 18:953-961.
225. Zhu FX KS, Smith EJ, Levy DE, Yuan Y (2002) A Kaposi's sarcoma-associated herpesviral protein inhibits virus-mediated induction of type I interferon by blocking IRF-7 phosphorylation and nuclear accumulation. Proceedings of the National Academy of Sciences USA 99:5573-5578.